These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31194283)

  • 21. Influence of pretransplant class I and II non-donor-specific anti-HLA immunization on immunologic outcome and graft survival in kidney transplant recipients.
    Staeck A; Khadzhynov D; Kleinsteuber A; Lehner L; Duerr M; Budde K; Lachmann N; Halleck F; Staeck O
    Transpl Immunol; 2020 Dec; 63():101333. PubMed ID: 32919027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretransplant Calculated Panel Reactive Antibody in the Absence of Donor-Specific Antibody and Kidney Allograft Survival.
    Lan JH; Kadatz M; Chang DT; Gill J; Gebel HM; Gill JS
    Clin J Am Soc Nephrol; 2021 Feb; 16(2):275-283. PubMed ID: 33495290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival.
    Michielsen LA; Wisse BW; Kamburova EG; Verhaar MC; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JF; Hepkema BG; Lambeck AJ; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens M; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG; van Zuilen AD
    Nephrol Dial Transplant; 2019 Jun; 34(6):1056-1063. PubMed ID: 30365008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
    Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
    Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential Impact of Delayed Graft Function in Deceased Donor Renal Transplant Recipients With and Without Donor-specific HLA-antibodies.
    Haller J; Wehmeier C; Hönger G; Hirt-Minkowski P; Gürke L; Wolff T; Steiger J; Amico P; Dickenmann M; Schaub S
    Transplantation; 2019 Sep; 103(9):e273-e280. PubMed ID: 31205266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
    Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
    Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. De Novo Donor-Specific Human Leukocyte Antigen Antibody Screening in Kidney Transplant Recipients After the First Year Posttransplantation: A Medical Decision Analysis.
    Kiberd BA; Miller A; Martin S; Tennankore KK
    Am J Transplant; 2016 Nov; 16(11):3212-3219. PubMed ID: 27106124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients.
    Comoli P; Cioni M; Tagliamacco A; Quartuccio G; Innocente A; Fontana I; Trivelli A; Magnasco A; Nocco A; Klersy C; Rubert L; Ramondetta M; Zecca M; Garibotto G; Ghiggeri GM; Cardillo M; Nocera A; Ginevri F
    Am J Transplant; 2016 Jul; 16(7):2106-16. PubMed ID: 26725780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical relevance of pre- and post-transplant HLA antibodies, donor-specific, and nondonor-specific HLA antibodies detected by ELISA in renal transplantation.
    Lee PC; Chen YL; Wang WM; Tu WC; Chen HY
    Clin Transpl; 2013; ():385-91. PubMed ID: 25095533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inferior long-term allograft and patient outcomes among recipients of offspring living donor kidneys.
    Cohen JB; Owei L; Sawinski DL; Porrett PM
    Am J Transplant; 2018 Jul; 18(7):1699-1709. PubMed ID: 29266831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subclass analysis of donor HLA-specific IgG in antibody-incompatible renal transplantation reveals a significant association of IgG4 with rejection and graft failure.
    Khovanova N; Daga S; Shaikhina T; Krishnan N; Jones J; Zehnder D; Mitchell D; Higgins R; Briggs D; Lowe D
    Transpl Int; 2015 Dec; 28(12):1405-15. PubMed ID: 26264744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
    Schwaiger E; Eskandary F; Kozakowski N; Bond G; Kikić Ž; Yoo D; Rasoul-Rockenschaub S; Oberbauer R; Böhmig GA
    Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
    Li X; Ishida H; Yamaguchi Y; Tanabe K
    Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
    Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA
    Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term results of desensitization protocol with and without rituximab in sensitized kidney transplant recipients.
    Green H; Nesher E; Aizner S; Israeli M; Klein T; Zakai H; Rahamimov R; Rozen-Zvi B; Mor E
    Clin Transplant; 2019 Jun; 33(6):e13562. PubMed ID: 30941818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
    Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN
    Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HLA Class II Antibodies at the Time of Kidney Transplantation and Cardiovascular Outcome: A Retrospective Cohort Study.
    Malfait T; Emonds MP; Daniëls L; Nagler EV; Van Biesen W; Van Laecke S
    Transplantation; 2020 Apr; 104(4):823-834. PubMed ID: 31369517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical utility of complement-dependent C3d assay in kidney recipients presenting with late allograft dysfunction.
    Lan JH; Gjertson D; Zheng Y; Clark S; ; Reed EF; Cecka MJ
    Am J Transplant; 2018 Dec; 18(12):2934-2944. PubMed ID: 29659162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
    Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
    Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.